Promising drug may help kids with rare cancer before transplant
NCT ID NCT05656248
First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 25 times
Summary
This study is testing an investigational drug called CPX-351 in 25 people under age 22 who have secondary myeloid neoplasms (a type of blood cancer that develops after previous cancer treatment). The goal is to see if the drug can safely put the cancer into remission before a stem cell transplant. Participants receive one or two courses of CPX-351, and researchers monitor remission rates and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOID NEOPLASM are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
St. Jude Children's Research Hospital
Memphis, Tennessee, 38105, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.